Syschem India Q2 FY26-27: Steady operations in a softer quarter
Ask Iris
Frequently Asked Questions
The deck is titled Performance Review and Business Results for FY26-27 and specifically references 2nd quarter results FY26-27.
The presentation lists Amoxicillin T/H, Ampicillin T/H, Flucloxacillin sodium, Cloxacillin sodium, Cephalexin, and Cephadroxil as key products.
The business performance section states that PBT was impacted primarily by significant foreign exchange rate fluctuations and heightened volatility in global financial markets.
The deck mentions development of dedicated Amoxicillin and other product plants including Cloxacillin sodium, Flucloxacillin sodium, and Dicloxacillin sodium to enhance manufacturing capacity.
The company states it is focused on achieving WHO-GMP certification to strengthen global quality standards and regulatory compliance.
The geographic expansion slide lists Afghanistan, Bangladesh, China, Kenya, Nepal, Congo, Uganda, Rwanda, Nigeria, Thailand, Cambodia, and Sri Lanka.
Did your stocks survive the war?
See what broke. See what stood.
Live Q1 Earnings Tracker